• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Lack of awareness of Chagas disease in the US leading to unnecessary deaths in vulnerable immigrant communities

New DNDi/CECD/MSF paper published in PLOS Neglected Tropical Diseases on the “silent killer” Chagas disease

Home > Press releases

Lack of awareness of Chagas disease in the US leading to unnecessary deaths in vulnerable immigrant communities

New DNDi/CECD/MSF paper published in PLOS Neglected Tropical Diseases on the “silent killer” Chagas disease

New York/Los Angeles, USA — 26 Sep 2019
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Español

Fear, stigma, gaps in the health system, and lack of awareness in the medical community are among the barriers keeping the most vulnerable from accessing essential care for Chagas disease, a leading cause of heart disease in the Americas, according to a paper published today by the not-for-profit drug development organization Drugs for Neglected Diseases initiative (DNDi), the Center of Excellence for Chagas Disease (CECD) at Olive View-UCLA Medical Center, and the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF).

Appearing in PLOS Neglected Tropical Diseases, this paper examines why only 0.3% of the more than 300,000 people living with Chagas in the US have received potentially life-saving treatment for this neglected disease, which is transmitted by blood-sucking “kissing” bugs. While Chagas is transmitted within the US by native kissing bugs, most patients living with the disease were born in Latin America, and today face multiple barriers to accessing healthcare. Chagas can cause life-threatening heart damage and gastrointestinal complications if not treated early

The authors note that widening political and economic inequalities, intersecting with anti-immigrant sentiments, severely limit the ability of many people with Chagas disease to access care. An estimated 30% of those living with Chagas in the US are undocumented.

“The neglect of people living with Chagas disease is another example of how the current environment is having an impact on the health of immigrant communities in the US,” said Dr Sheba Meymandi, Director of the CECD at Olive View-UCLA Medical Center and an author of the paper. “It is hard to get treated when you’re in a job that won’t provide time off, and you have to take a three hour bus ride to get to an appointment, and then your doctor doesn’t know what you’re talking about when you bring up Chagas disease.”

The CECD is the only US provider fully dedicated to comprehensive health for Chagas disease. Since 2007 it has screened 8,000 patients for Chagas disease – often through health fairs in Los Angeles. But unfortunately, the CECD is a rarity in the US. As the authors point out, most health care providers in the US are unfamiliar with the disease. Chagas is a “silent disease” and by the time symptoms appear treatment may be less effective, making it important to test people who might be at risk as early as possible.

Based on the CECD’s experience in Los Angeles, the authors propose strengthening screening and public awareness programmes, bolstering education of healthcare personnel, and ensuring screening and treatment are freely available to people at risk of the disease. Increased investments to improve diagnosis and simplify treatment will also be critical to improving care for people with Chagas disease.

 

Woman sitting at a table

Read stories of people living with Chagas disease in the US, including those that were infected without ever leaving the country.

Story – Voices of Chagas in the USA

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. Since its inception in 2003, DNDi has delivered eight new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. www.dndi.org

About MSF

Doctors Without Borders/Médecins Sans Frontières (MSF) is an international, independent medical humanitarian organization working in more than 70 countries to assist people affected by armed conflict, epidemics, health care exclusion, and natural or man-made disasters. Learn more here: www.doctorswithoutborders.org

About the CECD

Housed within the Olive View-UCLA Medical Center in Sylmar, California, the Center of Excellence for Chagas Disease (CECD) is the only organization in the United States fully dedicated to providing comprehensive care for people affected by Chagas disease. www.chagasus.org

Media contact

DNDi North America
Ilan Moss
Tel: +1 646 266 5216
imoss@dndi.org

Photo credit: Angela Boatwright-DNDi

Chagas disease

Read, watch, share

Loading...
Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

Statements
12 Apr 2022

DNDi intervention at the Intergovernmental Negotiating Body first round of public hearings

Dr Monique Wasunna, Eastern Africa Regional Director, DNDi; Carole Lanteri, Ambassador and Permanent Representative at UNOG for the Government of the Principality of Monaco; Dr Bernard Pécoul, Executive Director, DNDi
Press releases
8 Apr 2022

Government of the Principality of Monaco supports DNDi to increase access to improved treatment for children with HIV

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License